crackedtooth schreef:
Korte samenvatting 2008 van cpneln en dit zijn idd de key issues:
Key takeaways.........
1. "The sale of our FOB assets to Merck represents a WATERHSHED MOMENT for Insmed," said Dr. Geoffrey Allan, Ph.D., President and CEO Insmed."
2. "This agreement demonstrates Insmed's world-class clinical capabilities, and provides us with a SUBSTANTIAL CASH infusion that positions us well for FUTURE GROWTH."
3. " In the short-term, we expect to be CASH NEUTRAL for the balance of 2009 as we continue moving ahead with our IPLEX(TM) programs for MMD and ALS."
4. " In addition, we intend to pursue a comprehensive and thoughtful analysis to determine the most appropriate use of the proceeds we will receive from Merck. Our objective, though, is to utilize this capital to GROW our business, and CREATE SHAREHOLDER VALUE, as we have done through the transaction with Merck."
------------------------
2008 annual report
investorshub.advfn.com/boards/read_ms...